Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this randomized controlled clinical trial is to compare the therapeutic effect of moxibustion on allergic rhinitis. The main questions it aims to answer are:
Based on randomized controlled trials, verify the effectiveness of moxibustion in treating allergic rhinitis Based on a real-time monitoring system for human surface temperature, discuss the differences in therapeutic effects of different moxibustion doses on allergic rhinitis
Allergic rhinitis has a high incidence and is difficult to cure, seriously affecting the quality of life of patients Compare the effects of different moxibustion durations on the clinical efficacy and body surface temperature of patients with allergic rhinitis, and preliminarily explore the impact of different moxibustion doses on the efficacy of heavy moxibustion treatment for allergic rhinitis, providing evidence-based basis for clinical practice.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ordinary moxibustion volume group | Placebo Comparator |
| |
| First group of heavy moxibustion | Experimental |
| |
| Second groups of heavy moxibustion | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ordinary moxibustion volume group | Behavioral | Moxibustion for 10 minutes per acupoint |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rhinitis VAS Visual Analog Scale（AR-VAS） | VAS will be used to evaluate the relief of rhinitis symptoms, with a total score of 0-10. The higher the score, the more severe the symptoms will be | Change from baseline VAS scores at week 0(before treatment)，4 and 12. |
| Total nasal symptom scores（TNSS） | The main symptoms of allergic rhinitis, the higher the score, the worse the condition | Change from baseline TNSS scores at week 0(before treatment)，4 and 12. |
| Measure | Description | Time Frame |
|---|---|---|
| Total non nasal symptom scores（TNNSS） | The nasal accompanying symptoms of allergic rhinitis, qualitative evaluation of the severity of the disease, with some indicating severity and none indicating milder severity | Change from baseline TNNSS scores at week0(before treatment)，4 and 12. |
| Rhino-conjunctivitis Quality of Life Questionnaire （RQLQ） |
Not provided
Inclusion criteria
Exclusion criteria
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yang Xie, MD | Contact | 0371-66248624 | xieyanghn@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Yang Xie, MD | Henan University of Traditonal Chinese Medicine | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of Henan University of Chinese Medicine | Recruiting | Zhengzhou | China |
Not provided
| ID | Term |
|---|---|
| D065631 | Rhinitis, Allergic |
| ID | Term |
|---|---|
| D012220 | Rhinitis |
| D009668 | Nose Diseases |
| D012140 | Respiratory Tract Diseases |
| D012130 | Respiratory Hypersensitivity |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| First group of heavy moxibustion | Behavioral | Moxibustion for 20 minutes per acupoint |
|
| Second groups of heavy moxibustion | Behavioral | Moxibustion for 30 minutes per acupoint |
|
RQLQ consists of 28 items, including daily life (1-3), sleep (4-6), non nasal eye symptoms (7-13), life problems (14-16), nasal symptoms (17-20), eye symptoms (21-24), and emotions (25-28). In the 7-point system, 1 point is the best and 7 points are the worst. |
| Change from baseline RQLQ scores at week0(before treatment)，4 and 12. |
| Detection of serum IgE and IL-33 levels | Immunoglobulin IgE and serum inflammatory cytokine IL-33 levels | Week0(before treatment), week 4（after treatment）. |
| D010038 |
| Otorhinolaryngologic Diseases |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |